Halozyme price target raised to $75 from $65 at Wells Fargo

Wells Fargo raised the firm’s price target on Halozyme (HALO) to $75 from $65 and keeps an Equal Weight rating on the shares. The firm sees the company’s near-term outlook as stable, driven by robust growth from Vyvgart and Darzalex. Still, progress in clinical development of next-generation subQ technologies remains to be the key for Halozyme’s long-term outlook, in Wells’ view.